Program
iloperidone
Also written as “Iloperidone”, “Iloperidone 1 MG” and “iloperidone (oral tablet)”.
Its studies are mostly in Schizophrenia · Hypertension · Parkinson Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticals | 103 open or running | phase 4since Dec 5, 2022 | Nov 10, 2005 | Nov 2027phase 3 · NCT06961968 |
| CSPC Pharmaceutical Group | 20 open or running | phase 3since May 19, 2015 | May 19, 2015 | none ahead |
| Novartis | 20 open or running | phase 4since Sep 19, 2010 | Sep 19, 2010 | none ahead |
| Hansoh Pharmaceutical Group | 10 open or running | phase 2since Jun 17, 2012 | Jun 17, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 10, 2005.
- Feb 3, 2011Phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT01291511 · 635 enrolled · United States, India, Ukraine
- Aug 31, 2011Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT01495169 · 33 enrolled · United States
- Sep 23, 2011Phase 1 study in Hepatic ImpairmentNovartis · NCT01529294 · 90 enrolled · United States
- Jun 17, 2012Hansoh Pharmaceutical Group's first study: phase 2 study in SchizophreniaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT01623713 · 260 enrolled · China
- May 19, 2015CSPC Pharmaceutical Group's first study: phase 3 study in SchizophreniaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT02453893 · 288 enrolled · China
- Jan 19, 2018Phase 1 study in BioequivalenceCSPC Pharmaceutical Group · NCT03420534 · 36 enrolled · China
- Oct 7, 2019Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT04127058 · 12 enrolled · United States
- Jan 13, 2021Phase 1 study in SchizophreniaVanda Pharmaceuticals · NCT04712734 · 42 enrolled · United States
- Mar 24, 2021Phase 3 study in Bipolar I DisorderVanda Pharmaceuticals · NCT04819776 · 417 enrolled · United States, Bulgaria, Poland
- Apr 18, 2022Phase 2 study in Parkinson Disease PsychosisVanda Pharmaceuticals · NCT05344365 · United States
- Dec 5, 2022Phase 4 study in SchizophreniaVanda Pharmaceuticals · NCT05648591 · 100 planned · United States
- Apr 29, 2025Phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT06961968 · 400 planned · United States
- Jul 22, 2025Phase 2 study in HypertensionVanda Pharmaceuticals · NCT07090161 · 240 planned · United States
- Oct 1, 2026Primary completion moved from 2026-03-31 to 2028-12-31Date moved laterphase 4 · +33 months · NCT05648591
Ahead
- Nov 2027Primary completion: phase 3 study in SchizophreniaVanda Pharmaceuticals · NCT06961968
- Dec 31, 2028Primary completion: phase 4 study in SchizophreniaVanda Pharmaceuticals · NCT05648591
TargetBeta
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07090161Hypertension · United States | 2 | Recruiting | Vanda Pharmaceuticals | Oct 2026 | 240 |
| NCT06961968Schizophrenia · United States | 3 | Recruiting | Vanda Pharmaceuticals | Nov 2027 | 400 |
| NCT05648591Schizophrenia · United States | 4 | Recruiting | Vanda Pharmaceuticals | Dec 31, 2028 | 100 |
| NCT05344365Parkinson Disease Psychosis · United States | 2 | Withdrawn | Vanda Pharmaceuticals | Nov 2023 | 0 |
| NCT04819776Bipolar I Disorder · United States, Bulgaria, Poland | 3 | Completed | Vanda Pharmaceuticals | Sep 7, 2022 | 417 |
| NCT04712734Schizophrenia · United States | 1 | Completed | Vanda Pharmaceuticals | Aug 30, 2022 | 42 |
| NCT04127058Schizophrenia · United States | 1 | Completed | Vanda Pharmaceuticals | Nov 27, 2019 | 12 |
| NCT03420534Bioequivalence · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 14, 2017 | 36 |
| NCT02453893Schizophrenia · China | 3 | UNKNOWN | CSPC Pharmaceutical Group | Jun 2015 | 288 |
| NCT01623713Schizophrenia · China | 2 | Completed | Hansoh Pharmaceutical Group | Oct 2013 | 260 |
| NCT01529294Hepatic Impairment · United States | 1 | Completed | Novartis | Jul 2012 | 90 |
| NCT01495169Schizophrenia · United States | 1 | Completed | Vanda Pharmaceuticals | Feb 2015 | 33 |
| NCT01291511Schizophrenia · United States, India, Ukraine | 3 | Completed | Vanda Pharmaceuticals | Mar 2014 | 635 |
| NCT01207414Schizophrenia · United States | 4 | Completed | Novartis | Jan 2012 | 501 |
| NCT00254202Schizophrenia · United States, India | 3 | Completed | Vanda Pharmaceuticals | Sep 26, 2006 | 593 |
How it is read
Names in the registry
- “Iloperidone”, 9 entries
- “iloperidone”, 4 entries
- “Iloperidone 1 MG”, 1 entry
- “iloperidone (oral tablet)”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 10 studies
- Hypertension, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.